Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44,381 result(s) found. Displaying page 1,584 of 2,220.
    «« First « Previous 1580  1581  1582  1583  1584  1585  1586  1587  1588  Next» Last»»
    EudraCT Number: 2019-001793-28 Sponsor Protocol Number: 371b Start Date*: 2019-11-05
    Sponsor Name:Reade
    Full Title: Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial
    Medical condition: Rheumatoid arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002431-18 Sponsor Protocol Number: NN9536-4451 Start Date*: 2019-09-25
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 2.4 mg once weekly on weight management in adolescents with overweight or obesity
    Medical condition: Overweight Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10033307 Overweight PT
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) BE (Completed) IE (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001268-20 Sponsor Protocol Number: EP0073 Start Date*: 2015-08-13
    Sponsor Name:UCB Biopharma SRL
    Full Title: AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF UCB0942 WHEN USED AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET SEIZURES IN ADULT SUBJECTS WITH...
    Medical condition: highly drug-resistant focal epilepsy
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10065337 Focal epilepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) BE (Completed) BG (Completed) HU (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002023-41 Sponsor Protocol Number: CRC1 Start Date*: 2013-10-28
    Sponsor Name:VU University Medical Center
    Full Title: Image guided treatment optimalization with cetuximab for patients with metastatic colorectal cancer: IMPACT - CRC
    Medical condition: metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-004557-14 Sponsor Protocol Number: NA Start Date*: 2015-02-09
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King’s College Hospital NHS Foundation Trust
    Full Title: Prospective randomised marker-based trial to assess the clinical utility and safety of biomarker-guided immunosuppression withdrawal in liver transplantation
    Medical condition: Immunosuppression withdrawal in liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) ES (Prematurely Ended) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001543-30 Sponsor Protocol Number: R3500-AD-1798 Start Date*: 2019-06-11
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2A STUDY TO ASSESS THE EFFICACY AND SAFETY OF REGN3500 MONOTHERAPY AND COMBINATION OF REGN3500 PLUS DUPILUMAB IN ADULT PATIENTS WITH MODERATE-T...
    Medical condition: Moderate to Severe Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002821-45 Sponsor Protocol Number: AC-055H302 Start Date*: 2019-03-05
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Prospective, multi-center, single-arm, open-label long-term study assessing the safety, tolerability, and effectiveness of macitentan in Fontan-palliated adult and adolescent subjects
    Medical condition: Congenital Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10045545 Univentricular heart PT
    20.0 10042613 - Surgical and medical procedures 10065950 Cavopulmonary anastomosis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) DK (Completed) PL (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2020-000126-26 Sponsor Protocol Number: V419-013 Start Date*: 2020-07-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Hepatitis B Vaccine Challenge Study to Demonstrate the Durability of Protection Against Hepatitis B Virus Infection in Healthy Children Vaccinated Approximately 9 Years Previously With a 2- or 3-...
    Medical condition: Long-term protection against HBV infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10019743 Hepatitis B virus (HBV) LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2020-002201-25 Sponsor Protocol Number: CHDR2007 Start Date*: 2020-12-14
    Sponsor Name:Centre for Human Drug Research
    Full Title: A two-part (observational and intervention) study to explore disease characteristics of vulvar (pre)malignancies compared to healthy volunteers
    Medical condition: lichen sclerosus, vulvar (pre)malignancies
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004882-15 Sponsor Protocol Number: STOP-NUC Start Date*: 2014-10-30
    Sponsor Name:Universität Leipzig
    Full Title: A multicentre randomized controlled trial evaluating the rate of sustained remission and the safety when stopping nucleos(t)ide analogue treatment in non-cirrhotic HBeAg-negative chronic Hepatitis ...
    Medical condition: HBeAg negative chronic Hepatitis B virus (HBV) infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004675-13 Sponsor Protocol Number: WIL-31 Start Date*: Information not available in EudraCT
    Sponsor Name:Octapharma AG
    Full Title: CLINICAL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF WILATE DURING PROPHYLAXIS IN PREVIOUSLY TREATED PATIENTS WITH VON WILLEBRAND DISEASE (VWD)
    Medical condition: Von Willebrand disease, type 3, type 2 (except 2N), or severe type 1
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10055168 Von Willebrand's factor deficiency LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BG (Completed) HU (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-000400-26 Sponsor Protocol Number: 201842 Start Date*: 2015-12-15
    Sponsor Name:GlaxoSmithKline R&D Ltd
    Full Title: A randomized, double blind (sponsor open), comparative, multicenter study to evaluate the safety and efficacy of subcutaneous belimumab (GSK1550188) and intravenous rituximab coadministration in su...
    Medical condition: Primary Sjogrens disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10061664 Autoimmune disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003650-88 Sponsor Protocol Number: BAY94-9343/15743 Start Date*: 2015-11-25
    Sponsor Name:Bayer AG
    Full Title: A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94-9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma ov...
    Medical condition: Patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10035605 Pleural mesothelioma malignant advanced LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DE (Completed) BE (Completed) GB (Completed) ES (Completed) NL (Completed) PL (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002668-28 Sponsor Protocol Number: HP-301 Start Date*: 2020-04-21
    Sponsor Name:Phathom Pharmaceuticals, Inc.
    Full Title: A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy with Oral Vonoprazan 20 mg or Double-Blind Triple Therapy with Oral Vonoprazan 20 mg Compared t...
    Medical condition: Helicobacter pylori infection
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004862 10019377 Helicobacter pylori infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-002009-25 Sponsor Protocol Number: SARSCov2EFTI1.0 Start Date*: 2020-10-01
    Sponsor Name:Fakultní nemocnice Plzeň
    Full Title: The efficacy and safety of Eftilagimod Alpha Treatment by immune modulation in COVID-19 disease (EAT COVID trial)
    Medical condition: COVID-19 disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2019-004901-28 Sponsor Protocol Number: EDP1815-201 Start Date*: 2020-03-31
    Sponsor Name:Evelo Biosciences Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort, Dose-Ranging Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
    Medical condition: Mild to Moderate Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) PL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2015-001852-32 Sponsor Protocol Number: 3475-164 Start Date*: 2015-12-11
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase II Study of Pembrolizumab (MK-3475) as Monotherapy in Subjects with Previously Treated Locally Advanced Unresectable or Metastatic (Stage IV) Mismatched Repair Deficient or Microsatellite I...
    Medical condition: Colorectal Carcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2007-002061-12 Sponsor Protocol Number: SBG2004-1/ABCSG25/GBG53 Start Date*: 2007-08-17
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: PANTHER (The SBG 2004-1/ABCSG 25/GBG53 Protocol) - a randomised phase III study: Comparing two weekly and tailored epirubicin + cyclophosphamide followed by two weekly tailored docetaxel (dtEC->dtT...
    Medical condition: lymph node positive breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) FI (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-002856-34 Sponsor Protocol Number: LTx18-01 Start Date*: 2019-03-01
    Sponsor Name:Foundation for Liver research
    Full Title: Modifying tacrolimus related toxicity after liver transplantation. A randomized controlled trial comparing Envarsus® and Advagraf® in de novo liver transplant recipients.
    Medical condition: liver transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10024715 Liver transplant rejection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004364-21 Sponsor Protocol Number: FYB202-03-01 Start Date*: 2020-05-12
    Sponsor Name:bioeq GmbH
    Full Title: A Randomised, Double-blind, Parallel-group, Phase 3 Study to Compare the Efficacy, Safety, and Immunogenicity of the Proposed Biosimilar Ustekinumab FYB202 to Stelara in Patients with Moderate-to-S...
    Medical condition: Moderate-to-Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1580  1581  1582  1583  1584  1585  1586  1587  1588  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 08:54:38 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA